首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1593480

老龄化黄斑部病变市场规模、份额、成长分析、按产品类型、按分子类型、按核准类型、按 AMD 类型、按最终用户、按地区 - 行业预测，2024-2031 年

Age-related Macular Degeneration Market Size, Share, Growth Analysis, By Product, By Molecule, By Approval Type, By Type of AMD By End User, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月09日 | 出版商:

SkyQuest | 英文 193 Pages | 商品交期: 3-5个工作天内

价格

简介目录

老龄化黄斑部病变（AMD）的全球市场规模在2022年估值为92亿美元，从2023年的101.9亿美元增长到2031年的231.6亿美元，在预测期内（2024-2024年）预计将以2031 年复合年增长率为 10.80%）。

老龄化黄斑部病变AMD 是老年人视力丧失的主要原因，主要影响视网膜中心的黄斑部。 AMD 有两种：干性 AMD 和湿性AMD，它们的进展率和治疗方法差异很大。干性 AMD 更为常见，通常可以透过改变生活方式和补充维生素来控制。另一方面，湿性AMD很少见，但需要更具侵入性的治疗，例如直接针对黄斑下异常血管生长的抗 VEGF 注射。这种治疗方法有效地抑制了导致这种生长的蛋白质，表明不同类型的 AMD 需要略有不同的医疗干预措施。随着世界人口老化，AMD 治疗市场正在扩大，这主要是由于老年人中该疾病的盛行率不断增加以及对药物治疗的依赖日益增加。随着越来越多的人寻求保护视力，这一趋势凸显了个人化医疗解决方案的重要性。因此，AMD 患者数量的迅速增加和药物干预的进步表明 AMD 药物市场强劲。随着越来越多的老年人采取生活方式改变和药物治疗来管理AMD，医疗保健提供者和製药公司越来越多地瞄准这一人群，该市场有望持续成长。治疗产品有很大的机会。

市场概况
北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲国家地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 其他亚太地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲 (MEA)
- 阿拉伯联合大公国国家
- 南非
- 其他中东/非洲地区

竞争格局

前5名企业对比
主要企业市场定位（2023年）
主要市场参与者所采取的策略
近期市集活动
主要企业市场占有率（2023年）

主要企业简介

Biogen（US）
Formycon AG（Germany）
Coherus Biosciences（US）
Biocon（India）
Outlook Therapeutics, Inc.（US）
Teva Pharmaceutical Industries Ltd.（Israel）
Intas Pharmaceuticals Ltd.（India）
Chengdu Kanghong Pharmaceutical Group Co., Ltd.（China）
Ocular Therapeutix, Inc.（US）
Opthea Limited（Australia）
Kodiak Sciences Inc.（US）
Bio-Thera（China）
Amgen Inc.（US）
Alvotech（Iceland）
Stealth Biotherapeutics Inc.（US）
Alteogen Inc.（South Korea）
Ocumension Therapeutics（China）
Innovent（China）
Regeneron Pharmaceuticals, Inc.（US）
Shanghai Henlius Biotech, Inc.（China）

简介目录

Product Code: SQMIG35I2357

Global Age-related Macular Degeneration Market size was valued at USD 9.2 billion in 2022 and is poised to grow from USD 10.19 billion in 2023 to USD 23.16 billion by 2031, growing at a CAGR of 10.80% during the forecast period (2024-2031).

Age-related macular degeneration (AMD), a leading cause of vision loss in the elderly, primarily affects the macula, the central area of the retina. The two prevalent forms of AMD-dry and wet-differ significantly in their progression and treatment approaches. Dry AMD is more common, often managed through lifestyle changes and vitamin supplementation, whereas wet AMD, though rarer, necessitates more invasive treatments, including anti-VEGF injections that directly target the abnormal blood vessel growth beneath the macula. This treatment method effectively inhibits the proteins responsible for such growth, illustrating the nuanced medical interventions required for different AMD types. As the global population ages, the market for AMD treatments is expanding, driven largely by the increasing prevalence of the disease among seniors and their growing reliance on medication. This trend underscores the importance of tailored healthcare solutions as more individuals seek to maintain their vision. Consequently, the surge in AMD cases, alongside advancements in pharmaceutical interventions, suggests a robust market trajectory for AMD therapies. With a rising number of seniors adopting lifestyle adjustments and medication for AMD management, the market is poised for sustained growth, indicating a significant opportunity for healthcare providers and pharmaceutical companies to innovate and expand their AMD treatment offerings in response to the evolving needs of this demographic.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Age-Related Macular Degeneration market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Age-Related Macular Degeneration Market Segmental Analysis

Global Age-related Macular Degeneration Market is segmented by Product, Molecule, Approval Type, Type of AMD, End User, and region. Based on Product, the market is segmented into Eylea & Eylea HD, Lucentis, Vabysmo, Syfovre, and Other Products. Based on Molecule, the market is segmented into Aflibercept, Faricimab, Ranibizumab, Pegcetacoplan, and Other Molecules. Based on Approval Type, the market is segmented into Biologics, and Biosimilars. Based on Type of AMD, the market is segmented into Wet AMD, and Dry AMD. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Age-Related Macular Degeneration Market

The global age-related macular degeneration (AMD) market is significantly driven by the increasing elderly population, as this demographic is more vulnerable to the onset of AMD due to age-related physiological changes. As life expectancy continues to rise globally, the prevalence of AMD is expected to escalate, leading to a heightened demand for effective therapies and treatments aimed at managing and preventing vision loss. This surge in cases not only emphasizes the need for advanced medical solutions but also stimulates innovation and investment in research and development of AMD-targeted interventions, thereby propelling the overall market growth and addressing the impending vision health crisis among seniors.

Restraints in the Global Age-Related Macular Degeneration Market

One significant market restraint for the global age-related macular degeneration (AMD) market is the inadequate screening and diagnostic infrastructure in many regions. This deficiency not only leads to poor patient outcomes but also causes treatment delays, as individuals often remain unaware of their condition until it progresses to a more severe stage. The lack of awareness and information regarding available diagnostic tools further exacerbates this issue, limiting early interventions that are crucial for effective management of AMD. Consequently, the inefficiencies in current therapeutic options arise, stifling overall market growth and hindering advancements in patient care for AMD.

Market Trends of the Global Age-Related Macular Degeneration Market

The Global Age-Related Macular Degeneration (AMD) market is witnessing a significant trend towards the development and adoption of long-acting therapies, particularly extended-duration anti-VEGF treatments. This shift aims to address longstanding compliance issues associated with frequent injection schedules, as these innovative therapies reduce the treatment burden on patients by extending the duration between doses. By enhancing patient adherence and improving clinical outcomes, long-acting therapies are poised to drive market growth amidst previous challenges faced by conventional treatments. As a result, the AMD market is evolving with a focus on patient-centered solutions, indicating a promising future for therapeutic innovations in this domain.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factor
Degree of Competition
Top Investment Pockets
Ecosystem of the Market
Technology Analysis
Pricing Analysis
Value Chain Analysis
Supply Chain Analysis
Patent Analysis
Customer & Buying Criteria Analysis
Case Study Analysis

Age-Related Macular Degeneration Drugs Market by Product

Market Overview
Eylea & Eylea HD
Lucentis
Vabysmo
Syfovre
Other Products

Age-Related Macular Degeneration Drugs Market by Molecule

Market Overview
Aflibercept
Faricimab
Ranibizumab
Pegcetacoplan
Other Molecules

Age-Related Macular Degeneration Drugs Market by Approval Type

Market Overview
Biologics
Biosimilars

Age-Related Macular Degeneration Drugs Market by Type of AMD

Market Overview
Wet AMD
Dry AMD

Age-Related Macular Degeneration Drugs Market by End User

Market Overview
Hospitals
Long-Term Care Facilities
Specialty Centers
Others

Age-Related Macular Degeneration Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Biogen (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Formycon AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Coherus Biosciences (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocon (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Outlook Therapeutics, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Intas Pharmaceuticals Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chengdu Kanghong Pharmaceutical Group Co., Ltd. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocular Therapeutix, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Opthea Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Kodiak Sciences Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Thera (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alvotech (Iceland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Stealth Biotherapeutics Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alteogen Inc. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ocumension Therapeutics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Innovent (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Shanghai Henlius Biotech, Inc. (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments